Mar. 30 at 12:15 AM
$BCRX was founded in 1986 (40 years ago). The graph shows its share price history over the last 32 years (since its 3/4/94 IPO when it closed @
$6.50 a share).
Had you purchased 100 shares 32 years ago, your
$650 investment would be worth
$933. Had you opted to purchase a
$650 FDIC insured CD with a federally insured bank earning 4% per annum, your
$650 investment would be worth
$2,280.
BCRX shares closed at
$11.13 on 12/22/2014 (per Yahoo Finance) which was the day BCRX disclosed its first FDA approval of Ravipab. BCRX closed at
$9.33 2 days ago (down 16.2% over the last 12 years).
3 weeks ago we provided a post showing that BCRX 10-year revenue multiple was in the lowest 5% of all commercial-stage bios (oncology & non). Only
$ARDX was lower
BCRX accumulated losses through 12/31/25 =
$1.5B
Is anyone aware of a data driven reason BCRX shareholder value is more likely maximized by operating as a going concern thru Orladeyo's patent expiration? If so please share?
$XBI $IBB $LABU
